Are skeletal muscle relaxants contraindicated in patients with hypermobile Ehlers‑Danlos syndrome?

Muscle Relaxants Are NOT Contraindicated in Ehlers-Danlos Syndrome

Skeletal muscle relaxants are not contraindicated in patients with hypermobile Ehlers-Danlos syndrome (hEDS), though their efficacy is limited and they should be used cautiously as part of a broader treatment strategy.

Evidence Base

The available guidelines and research do not identify muscle relaxants as contraindicated medications in hEDS. The most recent 2025 AGA guideline on hEDS 1 specifically lists medications to avoid when mast cell activation syndrome (MCAS) is present—including opioids and NSAIDs—but muscle relaxants are notably absent from this contraindication list.

Clinical Reality: Limited Efficacy, Not Contraindication

Real-world data shows muscle relaxants are commonly prescribed in hEDS but with disappointing results:

• In a retrospective cohort of 98 EDS patients, muscle relaxants were used but showed variable efficacy 2
• A 2011 study found that patients with high medication consumption (including muscle relaxants) actually had higher dysfunction in daily life, suggesting these medications may not address the underlying pathophysiology 3
• The general skeletal muscle relaxant literature acknowledges poor methodologic evidence for efficacy, with choice typically based on side-effect profile rather than superior outcomes 4

Key Caveats

When MCAS is Comorbid

If your patient has concurrent MCAS (common in hEDS), muscle relaxants may theoretically trigger mast cell degranulation, though this is not explicitly documented in the evidence. The 2025 guideline emphasizes avoiding "specific medications" that trigger MCAS 1, but does not name muscle relaxants specifically.

Better Alternatives Exist

The evidence strongly favors:

• Occupational therapy and bracing (70% improvement rate) 2
• Neuromuscular exercises over passive modalities 3
• Active stabilization strategies rather than pharmacologic muscle relaxation 5

Practical Algorithm

1. First-line: Occupational therapy, bracing, and active neuromuscular rehabilitation 2, 5
2. If pharmacotherapy needed: Consider neuropathic modulators (though 47% report adverse effects) 2
3. Muscle relaxants: May trial if other options fail, but set realistic expectations about limited efficacy
4. Screen for MCAS: If present, proceed with heightened caution and monitor for degranulation symptoms 1

Bottom Line

The absence of muscle relaxants from contraindication lists in the most recent 2025 guideline 1 is telling—they're not dangerous, just not particularly helpful. The real pitfall is over-relying on passive pharmacologic strategies when active rehabilitation demonstrates superior outcomes in this population.